ImageneBio Financial Statements From 2010 to 2026

IMA Stock   6.77  0.13  1.88%   
ImageneBio's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing ImageneBio's valuation are provided below:
Gross Profit
4.3 M
Market Capitalization
91.7 M
Enterprise Value Revenue
31.8591
Revenue
4.3 M
Earnings Share
(4.33)
We have found one hundred twenty available fundamental trends for ImageneBio, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to confirm all of ImageneBio regular market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. As of January 15, 2026, Market Cap is expected to decline to about 1.1 B. In addition to that, Enterprise Value is expected to decline to about 958.6 M

ImageneBio Total Revenue

3.82 Million

Check ImageneBio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ImageneBio's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.8 M, Selling General Administrative of 14.6 M or Total Revenue of 3.8 M, as well as many indicators such as Price To Sales Ratio of 296, Dividend Yield of 0.0 or PTB Ratio of 7.13. ImageneBio financial statements analysis is a perfect complement when working with ImageneBio Valuation or Volatility modules.
  
Build AI portfolio with ImageneBio Stock
Check out the analysis of ImageneBio Correlation against competitors.
For information on how to trade ImageneBio Stock refer to our How to Trade ImageneBio Stock guide.

ImageneBio Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets161.7 M162.7 M89.3 M
Slightly volatile
Short and Long Term Debt Total6.4 M6.8 M40.4 M
Slightly volatile
Other Current Liabilities6.1 MM3.8 M
Slightly volatile
Total Current Liabilities14.9 M9.7 M10.9 M
Slightly volatile
Property Plant And Equipment Net5.1 M4.9 M2.8 M
Slightly volatile
Current Deferred Revenue14.9 M10.5 M6.6 M
Slightly volatile
Accounts Payable1.5 M807.3 KM
Slightly volatile
Cash43 M45.3 M55.7 M
Slightly volatile
Non Current Assets Total8.7 M16.5 M5.1 M
Slightly volatile
Cash And Short Term Investments149.6 M143 M81.7 M
Slightly volatile
Common Stock Shares Outstanding38.9 M55.5 M37 M
Slightly volatile
Liabilities And Stockholders Equity161.7 M162.7 M89.3 M
Slightly volatile
Non Current Liabilities Total4.1 M4.3 M56.8 M
Slightly volatile
Other Current Assets3.4 M3.2 M2.5 M
Slightly volatile
Total Liabilities13.3 M14 M67.4 M
Pretty Stable
Total Current Assets153 M146.2 M84.3 M
Slightly volatile
Common Stock30.3 K55.2 K25.3 K
Slightly volatile
Non Currrent Assets Other12.2 M11.6 M3.2 M
Slightly volatile
Short Term Debt2.5 M4.4 M1.2 M
Slightly volatile
Short Term Investments63.4 M76.5 M90.7 M
Slightly volatile
Capital Lease Obligations612.4 K493.2 K906.8 K
Slightly volatile
Long Term Investments753.6 K847.8 K925.4 K
Slightly volatile
Property Plant And Equipment Gross759.2 K799.2 K6.3 M
Slightly volatile
Capital Stock20.9 M21.8 M19.3 M
Slightly volatile
Short and Long Term DebtM6.8 M7.4 M
Slightly volatile

ImageneBio Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1.8 M1.8 M692.9 K
Slightly volatile
Selling General Administrative14.6 M9.6 M8.2 M
Slightly volatile
Total Revenue3.8 MM5.8 M
Slightly volatile
Other Operating Expenses63.6 M46.6 M50 M
Slightly volatile
Research Development49 M36.9 M41.5 M
Slightly volatile
Cost Of Revenue418.9 K441 K31.4 M
Slightly volatile
Total Operating Expenses34.9 M46.6 M37.4 M
Very volatile
Total Other Income Expense Net486.2 K511.8 K758.4 K
Slightly volatile
Tax Provision11.1 K11.7 K232.7 K
Slightly volatile
Net Interest Income627.2 K336.6 K1.1 M
Slightly volatile
Interest Income627.2 K336.6 K1.1 M
Slightly volatile
Reconciled Depreciation1.8 M1.4 M2.8 M
Slightly volatile

ImageneBio Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation4.5 M6.1 M2.5 M
Slightly volatile
Begin Period Cash Flow109.5 M139.3 M64.5 M
Slightly volatile
Depreciation592.4 K563.5 K488.3 K
Slightly volatile
End Period Cash Flow44 M46.3 M56.1 M
Slightly volatile
Other Cashflows From Financing Activities27.7 M35.2 M24.8 M
Slightly volatile
Total Cash From Financing Activities5.9 M6.2 M29.8 M
Pretty Stable

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio2963127.5 K
Slightly volatile
Stock Based Compensation To Revenue1.431.360.5647
Slightly volatile
Capex To Depreciation0.350.371.0018
Pretty Stable
EV To Sales2863027.5 K
Slightly volatile
Payables Turnover0.540.5715.01
Slightly volatile
Sales General And Administrative To Revenue1.322.162.2613
Slightly volatile
Research And Ddevelopement To Revenue10.5310.5523.5105
Slightly volatile
Capex To Revenue0.04940.0520.1894
Slightly volatile
Cash Per Share3.662.322.4716
Slightly volatile
Days Payables Outstanding699665182
Slightly volatile
Current Ratio6.310.626.6956
Slightly volatile
Capex Per Share0.00850.00890.0156
Slightly volatile
Revenue Per Share0.07920.08340.1786
Slightly volatile
Interest Debt Per Share0.170.180.9912
Slightly volatile
Debt To Assets0.05810.06111.6194
Slightly volatile
Days Of Payables Outstanding699665182
Slightly volatile
Ebt Per Ebit1.071.140.9983
Pretty Stable
Long Term Debt To Capitalization2.993.373.6732
Slightly volatile
Quick Ratio6.310.626.6956
Slightly volatile
Net Income Per E B T0.80.90.9804
Slightly volatile
Cash Ratio4.263.294.8716
Very volatile
Free Cash Flow Operating Cash Flow Ratio1.121.161.0346
Slightly volatile
Fixed Asset Turnover0.90.952.6874
Very volatile
Debt Ratio0.05810.06111.6194
Slightly volatile
Price Sales Ratio2963127.5 K
Slightly volatile
Asset Turnover0.0270.02840.0582
Very volatile

ImageneBio Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.1 B1.1 B4.1 B
Slightly volatile
Enterprise Value958.6 MB3.9 B
Slightly volatile

ImageneBio Fundamental Market Drivers

About ImageneBio Financial Statements

ImageneBio stakeholders use historical fundamental indicators, such as ImageneBio's revenue or net income, to determine how well the company is positioned to perform in the future. Although ImageneBio investors may analyze each financial statement separately, they are all interrelated. For example, changes in ImageneBio's assets and liabilities are reflected in the revenues and expenses on ImageneBio's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in ImageneBio. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue10.5 M14.9 M
Total RevenueM3.8 M
Cost Of Revenue441 K418.9 K
Stock Based Compensation To Revenue 1.36  1.43 
Sales General And Administrative To Revenue 2.16  1.32 
Research And Ddevelopement To Revenue 10.55  10.53 
Capex To Revenue 0.05  0.05 
Revenue Per Share 0.08  0.08 
Ebit Per Revenue(9.51)(9.99)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether ImageneBio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ImageneBio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Imagenebio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Imagenebio Stock:
Check out the analysis of ImageneBio Correlation against competitors.
For information on how to trade ImageneBio Stock refer to our How to Trade ImageneBio Stock guide.
You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ImageneBio. If investors know ImageneBio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ImageneBio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(4.33)
Revenue Per Share
0.011
The market value of ImageneBio is measured differently than its book value, which is the value of ImageneBio that is recorded on the company's balance sheet. Investors also form their own opinion of ImageneBio's value that differs from its market value or its book value, called intrinsic value, which is ImageneBio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ImageneBio's market value can be influenced by many factors that don't directly affect ImageneBio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ImageneBio's value and its price as these two are different measures arrived at by different means. Investors typically determine if ImageneBio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ImageneBio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.